Programmed death 1 (PD-1) monoclonal antibodies have been reported as a first-line therapeutic option for recurrent cervical cancer, especially for programmed death ligand 1 (PD-L1)-positive tumors. The gene discussed is CD274; the disease is cervical carcinoma.